Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-04-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2021年度独立董事述职报告（黄欣琪）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report for 2021" for Betta Pharmaceuticals Co., Ltd. It details the independent director's activities, attendance at board and committee meetings, opinions on various company matters, and efforts to protect investor rights during the 2021 fiscal year. The content focuses on the director's duties, meeting participation, and oversight rather than presenting financial statements or audit results. It is a report by an individual director about their role and activities, not a full company annual report, audit report, or regulatory filing. This type of document fits best under Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 4256 characters, which is consistent with a detailed director's report rather than a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2022-04-06 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 贝达药业股份有限公司 regarding their 24th meeting of the third Supervisory Board. It includes approvals of various reports such as the 2021 Supervisory Board Work Report, 2021 Financial Final Report, 2021 Annual Report, profit distribution plan, fundraising usage report, internal control self-evaluation report, and proposals related to auditor reappointment and cash management. The document states that these reports have been reviewed and approved by the Supervisory Board and will be submitted to the 2021 Annual General Meeting for further approval. The document itself does not contain the full reports but references that the full reports are disclosed elsewhere (e.g., on 巨潮资讯网). The document length is 3345 characters, which is relatively short and mainly serves as an announcement of the Supervisory Board meeting resolutions and approvals. According to the "Menu vs Meal" rule, since this document is short and mainly announces the approval of reports rather than containing the full reports themselves, it should be classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K) or other full reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-04-06 Chinese
2021年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the fiscal year 2021. It includes detailed audit opinions, key audit matters, and comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an auditor's opinion, detailed financial data, and extensive notes indicates this is a standalone audit report rather than a full annual report or a brief announcement. The document length is substantial (15,000 characters), and it contains actual financial data and audit details, not just a reference or announcement. Therefore, it fits the category of an Audit Report / Information (AR). FY 2021
2022-04-06 Chinese
2021年度关联方占用资金情况专项报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report for the fiscal year 2021 of 贝达药业股份有限公司, focusing on non-operating fund occupation and related party fund transactions. It includes detailed financial data tables and is issued by a certified public accounting firm. The document references the audit of the 2021 financial statements and compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content is a standalone audit report addressing specific financial issues, not a full annual report or a brief announcement. The length is 2530 characters, which is relatively short but contains substantive audited financial data and explanations. Therefore, it fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a Regulatory Filing (RNS). FY 2021
2022-04-06 Chinese
关于2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan of the company. It includes details about the profit allocation, dividend per share, and approvals from the board, supervisory committee, and independent directors. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. It is a formal announcement to shareholders about the dividend plan rather than the full annual report or earnings release. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is short (1655 characters), and it is not a report publication announcement or a certification. Hence, the classification is DIV with high confidence.
2022-04-06 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the use of idle funds for cash management by investing in low-risk, short-term principal-protected financial products. It details the investment purpose, amount, method, risk analysis, risk control measures, and the approval process including board and independent director opinions. The document is a formal disclosure about a financing activity related to the company's capital management, not a financial report or earnings release. It does not contain financial statements or detailed financial results but rather an update on capital usage and investment plans. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2578 characters, which is consistent with an announcement rather than a full report.
2022-04-06 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.